Improved binding affinity and pharmacokinetics enables sustained degradation of BCL6 in vivo. (October 2022) - Harnden, A.; Huckvale, R.; Cheung, K.M.; Davis, O.; Pierrat, O.; Talbot, R.; Box, G.; Bright, M.; Akpinar, A.; Miller, D.; Hayes, A.; Gunnell, E.; et al.